NASDAQ · Biotechnology · USD
Aardvark Therapeutics, Inc. (AARD) Stock Analysis
Aardvark Therapeutics, Inc. (AARD) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
AARD Key Statistics
As of Oct 21, 2026Trading
- Open
- $3.95
- Previous Close
- $3.90
- Day's Range
- 3.95–4.54
- 52-Week Range
- 3.35–16.60
- Volume
- 218.44K
Valuation
- Market Cap
- $96.51M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −3.21
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$57.59M
- Shares Outstanding
- 21.88M
- 1-Year Return
- −63.13%
Dividend and dates
- Earnings Date
- November 12, 2026estimated
- Avg Volume
- 129.05K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, AARD closed at $4.41, −63.13% over 1 year.
Aardvark Therapeutics, Inc. (AARD) has a market capitalization of $96.51M.
In fiscal 2025, AARD reported revenue of $0.00.
AARD Stock Return by Calendar Year
Aardvark Therapeutics, Inc. (AARD) return since Feb 2025: what $10,000 became
- 1 year
- $10,000 $3,687
- −63.13%
- Since Feb 2025
- $10,000 $3,082
- −69.18%
If you had invested $10,000 in Aardvark Therapeutics, Inc. (AARD) at the close on February 13, 2025, the earliest close on record here, it would have been worth $3,082 at the close on October 21, 2026: −69.18% in total, −50.30% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −66.40% |
| 2025 (partial year) | −8.28% |
As of October 21, 2026.
AARD Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$57.59M | — |
| 2024 | $0.00 | −$20.59M | — |
| 2023 | $0.00 | −$7.21M | — |
| 2022 | $0.00 | −$13.56M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$62.73M | −$57.59M | — |
| 2024 | $0.00 | — | −$22.67M | −$20.59M | — |
| 2023 | $0.00 | — | −$6.65M | −$7.21M | — |
| 2022 | $0.00 | — | −$10.87M | −$13.56M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
HC Wainwright & Co. Maintains Neutral on Aardvark Therapeutics, Lowers Price Target to $4
BenzingaAardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors
YahooAardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
YahooRBC Capital Reiterates Sector Perform on Aardvark Therapeutics, Maintains $6 Price Target
BenzingaAardvark Therapeutics Inc (AARD) (Q2 2026) Earnings Call Highlights: Board Re-Elected, Auditor ...
YahooAardvark Therapeutics Q2 EPS $(0.66) Beats $(0.91) Estimate
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B